Annual FCF
$51.65 M
+$7.29 M+16.42%
31 December 2023
Summary:
BioMarin Pharmaceutical annual free cash flow is currently $51.65 million, with the most recent change of +$7.29 million (+16.42%) on 31 December 2023. During the last 3 years, it has risen by +$103.80 million (+199.03%). BMRN annual FCF is now -72.13% below its all-time high of $185.31 million, reached on 31 December 2021.BMRN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$200.31 M
+$103.38 M+106.66%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly free cash flow is currently $200.31 million, with the most recent change of +$103.38 million (+106.66%) on 30 September 2024. Over the past year, it has increased by +$88.08 million (+78.48%). BMRN quarterly FCF is now at all-time high.BMRN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$300.88 M
+$88.08 M+41.39%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM free cash flow is currently $300.88 million, with the most recent change of +$88.08 million (+41.39%) on 30 September 2024. Over the past year, it has increased by +$269.59 million (+861.65%). BMRN TTM FCF is now at all-time high.BMRN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.4% | +78.5% | +861.6% |
| 3 y3 years | +199.0% | +161.2% | +82.1% |
| 5 y5 years | +141.5% | +476.9% | +388.3% |
BMRN Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -72.1% | +199.0% | at high | +302.9% | at high | +6947.6% |
| 5 y | 5 years | -72.1% | +141.5% | at high | +302.9% | at high | +361.3% |
| alltime | all time | -72.1% | +111.5% | at high | +192.4% | at high | +159.6% |
BioMarin Pharmaceutical Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $200.31 M(+106.7%) | $300.88 M(+41.4%) |
| June 2024 | - | $96.92 M(+653.3%) | $212.80 M(+30.4%) |
| Mar 2024 | - | $12.87 M(-239.7%) | $163.21 M(+216.0%) |
| Dec 2023 | $51.65 M(+16.4%) | -$9.21 M(-108.2%) | $51.65 M(+65.1%) |
| Sept 2023 | - | $112.23 M(+137.1%) | $31.29 M(-23.5%) |
| June 2023 | - | $47.33 M(-148.0%) | $40.91 M(+87.9%) |
| Mar 2023 | - | -$98.70 M(+233.7%) | $21.77 M(-50.9%) |
| Dec 2022 | $44.36 M(-76.1%) | -$29.57 M(-124.3%) | $44.36 M(+8.8%) |
| Sept 2022 | - | $121.85 M(+332.2%) | $40.76 M(-1027.5%) |
| June 2022 | - | $28.19 M(-137.0%) | -$4.39 M(-118.3%) |
| Mar 2022 | - | -$76.11 M(+129.4%) | $23.95 M(-87.1%) |
| Dec 2021 | $185.31 M(-455.3%) | -$33.18 M(-143.3%) | $185.31 M(+12.1%) |
| Sept 2021 | - | $76.70 M(+35.7%) | $165.24 M(+6.9%) |
| June 2021 | - | $56.53 M(-33.7%) | $154.59 M(+67.5%) |
| Mar 2021 | - | $85.26 M(-260.1%) | $92.31 M(-277.0%) |
| Dec 2020 | -$52.15 M(-54.7%) | -$53.25 M(-180.6%) | -$52.15 M(+2068.6%) |
| Sept 2020 | - | $66.05 M(-1249.1%) | -$2.40 M(-92.9%) |
| June 2020 | - | -$5.75 M(-90.3%) | -$33.74 M(-62.1%) |
| Mar 2020 | - | -$59.21 M(+1592.2%) | -$89.03 M(-22.7%) |
| Dec 2019 | -$115.14 M(-7.4%) | -$3.50 M(-110.1%) | -$115.14 M(+10.3%) |
| Sept 2019 | - | $34.72 M(-156.9%) | -$104.35 M(-26.4%) |
| June 2019 | - | -$61.03 M(-28.5%) | -$141.73 M(+3.4%) |
| Mar 2019 | - | -$85.33 M(-1269.7%) | -$137.07 M(+10.2%) |
| Dec 2018 | -$124.41 M(-40.2%) | $7.29 M(-374.4%) | -$124.41 M(-20.7%) |
| Sept 2018 | - | -$2.66 M(-95.3%) | -$156.98 M(-1.0%) |
| June 2018 | - | -$56.38 M(-22.4%) | -$158.51 M(+20.9%) |
| Mar 2018 | - | -$72.67 M(+187.5%) | -$131.12 M(-37.0%) |
| Dec 2017 | -$207.98 M(-44.7%) | -$25.28 M(+503.2%) | -$207.98 M(-11.3%) |
| Sept 2017 | - | -$4.19 M(-85.5%) | -$234.48 M(-12.1%) |
| June 2017 | - | -$28.98 M(-80.6%) | -$266.76 M(-13.7%) |
| Mar 2017 | - | -$149.53 M(+188.8%) | -$309.09 M(-17.8%) |
| Dec 2016 | -$376.22 M(-15.9%) | -$51.78 M(+42.0%) | -$376.22 M(-23.9%) |
| Sept 2016 | - | -$36.46 M(-48.9%) | -$494.09 M(-2.2%) |
| June 2016 | - | -$71.31 M(-67.1%) | -$505.03 M(+4.7%) |
| Mar 2016 | - | -$216.66 M(+27.7%) | -$482.17 M(+7.8%) |
| Dec 2015 | -$447.15 M(+138.5%) | -$169.66 M(+257.9%) | -$447.15 M(+35.8%) |
| Sept 2015 | - | -$47.41 M(-2.1%) | -$329.17 M(+4.3%) |
| June 2015 | - | -$48.45 M(-73.3%) | -$315.49 M(-1.1%) |
| Mar 2015 | - | -$181.64 M(+251.5%) | -$319.03 M(+70.2%) |
| Dec 2014 | -$187.48 M(+53.0%) | -$51.67 M(+53.2%) | -$187.48 M(+7.4%) |
| Sept 2014 | - | -$33.73 M(-35.1%) | -$174.56 M(+6.7%) |
| June 2014 | - | -$51.98 M(+3.8%) | -$163.53 M(+27.0%) |
| Mar 2014 | - | -$50.10 M(+29.3%) | -$128.77 M(+5.1%) |
| Dec 2013 | -$122.53 M(+354.4%) | -$38.75 M(+70.7%) | -$122.53 M(+43.0%) |
| Sept 2013 | - | -$22.69 M(+31.7%) | -$85.69 M(+34.3%) |
| June 2013 | - | -$17.23 M(-60.7%) | -$63.79 M(+11.0%) |
| Mar 2013 | - | -$43.85 M(+2197.3%) | -$57.47 M(+113.1%) |
| Dec 2012 | -$26.96 M(-80.1%) | -$1.91 M(+138.9%) | -$26.96 M(-76.6%) |
| Sept 2012 | - | -$799.00 K(-92.7%) | -$115.25 M(-28.8%) |
| June 2012 | - | -$10.90 M(-18.3%) | -$161.97 M(+16.2%) |
| Mar 2012 | - | -$13.35 M(-85.2%) | -$139.41 M(+2.7%) |
| Dec 2011 | -$135.80 M | -$90.19 M(+89.8%) | -$135.80 M(+88.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$47.53 M(-507.7%) | -$72.13 M(+189.4%) |
| June 2011 | - | $11.66 M(-219.7%) | -$24.92 M(-15.8%) |
| Mar 2011 | - | -$9.74 M(-63.3%) | -$29.60 M(-3.6%) |
| Dec 2010 | -$30.71 M(+1384.5%) | -$26.52 M(+8320.0%) | -$30.71 M(+318.1%) |
| Sept 2010 | - | -$315.00 K(-104.5%) | -$7.35 M(+42.5%) |
| June 2010 | - | $6.98 M(-164.3%) | -$5.16 M(-63.7%) |
| Mar 2010 | - | -$10.86 M(+244.2%) | -$14.21 M(+586.8%) |
| Dec 2009 | -$2.07 M(-96.8%) | -$3.15 M(-268.3%) | -$2.07 M(-72.5%) |
| Sept 2009 | - | $1.88 M(-190.5%) | -$7.52 M(-57.6%) |
| June 2009 | - | -$2.07 M(-261.5%) | -$17.76 M(-19.8%) |
| Mar 2009 | - | $1.28 M(-114.9%) | -$22.15 M(-66.2%) |
| Dec 2008 | -$65.54 M(+15.2%) | -$8.61 M(+3.0%) | -$65.54 M(+1.1%) |
| Sept 2008 | - | -$8.36 M(+29.3%) | -$64.82 M(-9.8%) |
| June 2008 | - | -$6.46 M(-84.6%) | -$71.83 M(-5.0%) |
| Mar 2008 | - | -$42.11 M(+433.7%) | -$75.64 M(+32.9%) |
| Dec 2007 | -$56.91 M(-25.9%) | -$7.89 M(-48.6%) | -$56.91 M(-12.5%) |
| Sept 2007 | - | -$15.36 M(+49.6%) | -$65.04 M(+0.5%) |
| June 2007 | - | -$10.27 M(-56.1%) | -$64.69 M(-19.0%) |
| Mar 2007 | - | -$23.38 M(+45.9%) | -$79.89 M(+4.1%) |
| Dec 2006 | -$76.75 M(+16.9%) | -$16.02 M(+6.7%) | -$76.75 M(-5.0%) |
| Sept 2006 | - | -$15.02 M(-41.0%) | -$80.80 M(-8.6%) |
| June 2006 | - | -$25.46 M(+25.8%) | -$88.38 M(+32.1%) |
| Mar 2006 | - | -$20.24 M(+0.8%) | -$66.90 M(+1.9%) |
| Dec 2005 | -$65.64 M(-12.6%) | -$20.08 M(-11.1%) | -$65.64 M(+7.5%) |
| Sept 2005 | - | -$22.59 M(+468.1%) | -$61.03 M(-3.1%) |
| June 2005 | - | -$3.98 M(-79.1%) | -$63.00 M(-22.0%) |
| Mar 2005 | - | -$18.98 M(+22.7%) | -$80.78 M(+7.5%) |
| Dec 2004 | -$75.12 M(-7.0%) | -$15.48 M(-37.0%) | -$75.12 M(-21.7%) |
| Sept 2004 | - | -$24.56 M(+12.9%) | -$95.97 M(+0.1%) |
| June 2004 | - | -$21.76 M(+63.3%) | -$95.92 M(+16.8%) |
| Mar 2004 | - | -$13.33 M(-63.3%) | -$82.13 M(+1.7%) |
| Dec 2003 | -$80.77 M(+38.2%) | -$36.32 M(+48.2%) | -$80.77 M(+2.1%) |
| Sept 2003 | - | -$24.50 M(+207.1%) | -$79.12 M(+31.3%) |
| June 2003 | - | -$7.98 M(-33.3%) | -$60.27 M(+0.7%) |
| Mar 2003 | - | -$11.97 M(-65.5%) | -$59.84 M(+2.4%) |
| Dec 2002 | -$58.46 M(-0.4%) | -$34.67 M(+513.6%) | -$58.46 M(+8.0%) |
| Sept 2002 | - | -$5.65 M(-25.2%) | -$54.14 M(-11.1%) |
| June 2002 | - | -$7.55 M(-28.6%) | -$60.89 M(+2.1%) |
| Mar 2002 | - | -$10.58 M(-65.2%) | -$59.66 M(+1.7%) |
| Dec 2001 | -$58.66 M(+255.7%) | -$30.36 M(+144.8%) | -$58.66 M(+78.8%) |
| Sept 2001 | - | -$12.40 M(+96.3%) | -$32.81 M(+44.2%) |
| June 2001 | - | -$6.32 M(-34.1%) | -$22.76 M(+16.0%) |
| Mar 2001 | - | -$9.58 M(+112.8%) | -$19.63 M(+19.0%) |
| Dec 2000 | -$16.49 M(-54.0%) | -$4.50 M(+91.6%) | -$16.49 M(-13.1%) |
| Sept 2000 | - | -$2.35 M(-26.2%) | -$18.97 M(-38.0%) |
| June 2000 | - | -$3.19 M(-50.6%) | -$30.62 M(-13.6%) |
| Mar 2000 | - | -$6.45 M(-7.6%) | -$35.46 M(-1.2%) |
| Dec 1999 | -$35.88 M(+147.5%) | -$6.98 M(-50.1%) | -$35.88 M(+24.2%) |
| Sept 1999 | - | -$14.00 M(+74.5%) | -$28.90 M(+94.0%) |
| June 1999 | - | -$8.02 M(+16.7%) | -$14.90 M(+116.7%) |
| Mar 1999 | - | -$6.88 M | -$6.88 M |
| Dec 1998 | -$14.50 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual free cash flow?
- What is the all time high annual FCF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual FCF year-on-year change?
- What is BioMarin Pharmaceutical quarterly free cash flow?
- What is the all time high quarterly FCF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly FCF year-on-year change?
- What is BioMarin Pharmaceutical TTM free cash flow?
- What is the all time high TTM FCF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM FCF year-on-year change?
What is BioMarin Pharmaceutical annual free cash flow?
The current annual FCF of BMRN is $51.65 M
What is the all time high annual FCF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual free cash flow is $185.31 M
What is BioMarin Pharmaceutical annual FCF year-on-year change?
Over the past year, BMRN annual free cash flow has changed by +$7.29 M (+16.42%)
What is BioMarin Pharmaceutical quarterly free cash flow?
The current quarterly FCF of BMRN is $200.31 M
What is the all time high quarterly FCF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly free cash flow is $200.31 M
What is BioMarin Pharmaceutical quarterly FCF year-on-year change?
Over the past year, BMRN quarterly free cash flow has changed by +$88.08 M (+78.48%)
What is BioMarin Pharmaceutical TTM free cash flow?
The current TTM FCF of BMRN is $300.88 M
What is the all time high TTM FCF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM free cash flow is $300.88 M
What is BioMarin Pharmaceutical TTM FCF year-on-year change?
Over the past year, BMRN TTM free cash flow has changed by +$269.59 M (+861.65%)